(REV) is a naturally occurring phytoalexin that inhibits neuronal K ϩ channels; however, the molecular mechanisms behind the effects of REV and the relevant ␣-subunit are not well defined. With the use of patch-clamp technique, cultured cerebellar granule cells, and HEK-293 cells transfected with the Kv2.1 and Kv2.2 ␣-subunits, we investigated the effect of REV on Kv2.1 and Kv2.2 ␣-subunits. Our data demonstrated that REV significantly suppressed Kv2.2 but not Kv2.1 currents with a fast, reversible, and mildly concentration-dependent manner and shifted the activation or inactivation curve of Kv2.2 channels. Activating or inhibiting the cAMP/PKA pathway did not abolish the inhibition of K v2.2 current by REV. In contrast, activation of PKC with phorbol 12-myristate 13-acetate mimicked the inhibitory effect of REV on K v2.2 by modifying the activation or inactivation properties of K v2.2 channels and eliminated any further inhibition by REV. PKC and PKC-␣ inhibitor completely eliminated the REVinduced inhibition of K v2.2. Moreover, the effect of REV on Kv2.2 was reduced by preincubation with antagonists of GPR30 receptor and shRNA for GPR30 receptor. Western blotting results indicated that the levels of PKC-␣ and PKC-␤ were significantly increased in response to REV application. Our data reveal, for the first time, that REV inhibited K v2.2 currents through PKC-dependent pathways and a nongenomic action of the oestrogen receptor GPR30. resveratrol; Kv2.2; GPR30; PKC RESVERATROL [trans-3= 4=,5=-trihydroxystilbene (REV)] is a naturally occurring phytochemical compound that is found in Ͼ70 plant species (11). Plants synthesize REV to protect against bacterial and fungal infections, stress, and injury (2, 25). Accumulating evidence indicates that REV mediates a wide range of biological activities, including increasing life span through anti-ischemic, anticancer, antiaging, and anti-inflammatory properties (23, 35, 37) . Although the chemical structure of REV indicates its antioxidant actions, previous studies suggest that REV
provide protection from brain ischemia. Furthermore, REV has been reported to provide maximal neuroprotection (41) and prevent the progression of acute seizures into chronic epilepsy and cognitive dysfunction (39) . Despite these clear neuronal effects, the molecular mechanisms underlying the neuroprotective and excitatory activities of REV have not been conclusively determined.
It is well established that voltage-gated K ϩ (K v ) channels determine neuronal action potential frequency, control the strength of synaptic contacts between neurons (20) , and play an important role in the regulation of neuronal apoptosis and survival (45) . This is especially true for the outward delayed rectifier (I K ) channels, due to their high K ϩ conductance and their non-or slow-inactivation behavior that occurs during membrane depolarization (32) . Thus the K v channels are considered as therapeutic targets (44) . Using the primary cultured rat hippocampal neurons, Gao and Hu (13) demonstrated that application of REV could reversibly inhibit I K channels. Furthermore, Gao and Hu (13) used extracellular recording techniques in hippocampal slices to demonstrate that REV inhibits neuronal discharges in the rat hippocampal CA1 area. In addition, REV suppresses epileptiform discharges in slices (12) , suggesting that the K ϩ channel is involved in REVinduced effects on neuronal protection and excitability. However, the relevant K v ␣-subunit and the molecular mechanism of REV-induced modulation on I K channels is not well defined.
Previous studies indicated that neuronal I K channels are composed of ␣-subunits from the K v 2 subfamily and that they are particularly important in regulating neuronal excitability and survival (16) . It was also reported that the K v 2.1 subunit, which is highly expressed in most mammalian central neurons, is a major contributor to I K channels and plays a crucial role in regulating neuronal excitability (8, 28) . Recently, the K v 2.2 channel was detected in brain areas; in addition, it maintains high frequency action potential firing (21, 22) and was modulated by the antidepressant citalopram (46) . In our present study, whole cell patch-clamp recordings of HEK-293 cells transfected with K v 2.1 and K v 2.2 ␣-subunits were used to examine the mechanistic effects of REV on the K v subunit of I K channels.
METHODS
Primary cultures of rat cerebellar granule neurons. SpragueDawley female rats were purchased from the Laboratory Animal Center of Shanghai at the Chinese Academy of Sciences (Shanghai, China). The cells were derived from the cerebellum of 7-day-old pups as described previously (15). Isolated cells were plated onto 35-mm Petri dishes coated with poly-L-lysine (1 g/ml) at a density of 10 6 cells/ml. Cultured cells were incubated at 37°C under 5% CO2 in DMEM supplemented with 10% fetal calf serum, insulin (5 g/ml), KCl (25 mM), and a 1% antibiotic-antimycotic solution. After 24 h in culture, cytosine b-D-arabinofuranoside (5 M) was added to the culture medium to inhibit the proliferation of nonneuronal cells. The experiments were performed using primary cerebellar granule neurons (CGNs) after 5-7 days in culture.
DNA construction and cell transfection. Total RNA was isolated from primary cultured rat cortical neurons according to the manufacturer's instructions (Qiagen Mini RNeasy; Qiagen, Valencia, CA). Firststrand synthesis was performed using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). Amplification was performed with the following primer sets: primer Kv2.2: forward, 5=-CCGCTCGAG ATG-GCAGAAAAGGCACCTCCTGGCTTGA-3= (XhoI); reverse, 5= GGA-ATTCGCATGCTGGTCTCACGAGTGGGGC-3 (EcoRI; GenBank NM_054000). Primer Kv2.1: forward, 5=-TGGCTCGAGATGCCG-GCGGGCATG 3= (XhoI); and reverse, 5=-ATACAGAATTCGGAT-ACTCTGATCCCT 3= (EcoRI; GenBank NM_008420). Rat Kv2.2 cDNA or Kv2.1 cDNA was ligated into pEGFPN1 by using XhoI and EcoRI restriction sites. Each gene was fused to the NH2 terminus of enhanced green fluorescent protein to enable detection of the transfected human embryonic kidney (HEK) 293 cells. All the constructs were verified by sequencing. The plasmids were extracted using a Qiagen plasmid midi kit (Qiagen). The DNA concentration and purity were determined by measuring the absorbance at 260 and 280 nm. HEK-293 cells were transfected using Lipofectamine 2000 (Invitrogen). The average transfection efficiency was Ͼ80%. Two days after transfection, HEK-293 cells with green fluorescence were further analyzed.
Patch-clamp recordings. Whole cell currents of HEK-293 cells were recorded using a patch-clamp technique. All currents were recorded using an Axopatch 200B amplifier (Axon Instrument, Foster City, CA) operated in voltage-clamp mode. A Pentium computer was connected to the recording equipment with a Digidata 1300 analogto-digital (A/D) interface. The current was digitally sampled at 100 s (10 kHz). The current signals were filtered by a 3-kHz, three-pole Bessel filter. Currents were corrected online for leak and residual capacitance transients with a P/4 protocol and current amplitude was analyzed by calculating the mean of the data points from 130 to 200 ms of a 200-ms pulse. This range was chosen because the I K amplitude was stable within this range. Data acquisition and analysis were performed with pClamp 8.01 software (Axon Instruments) and/or Origin7.5 (Microcal analysis software, Northampton, MA). Before IK channel current recording, the culture medium was replaced with a bath solution containing 145 mM NaCl, 2.5 mM KCl, 10 mM HEPES, and 1 mM MgCl2. Soft glass recording pipettes were filled with an internal solution containing 135 mM K gluconate, 10 mM KCl, 10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 10 mM EGTA, and 2 mM ATP (pH adjusted to 7.3 using KOH). The pipette resistance was 5-7 M⍀ after addition of the internal solution. All recordings were performed at room temperature (23-25°C) .
Western blot analysis of pPKC. Cells were lysed in HEPES-NP40 lysis buffer (20 mM HEPES, 150 mM NaCl, 0.5% NP-40, 10% glycerol, 2 mM EDTA, 100 M Na3VO4, 50 mM NaF pH 7.5, and 1% proteinase inhibitor cocktail) on ice for 30 min. After centrifugation, the supernatant was mixed with 2ϫ sodium dodecyl sulphate loading buffer and boiled for 5 min. The proteins were separated on a 10% SDS-polyacrylamide gel and then transferred to polyvinylidene difluoride membranes (Millipore, MA). The membrane was blocked with 10% nonfat milk and incubated at 4°C overnight with two types of rabbit polyclonal antibodies against the phosphorylated PKC-␣ and PKC-␤ or PKC-␦ and PKC-(1:4,000; Cell Signaling Technology, MA) or the mouse monoclonal antibody against GAPDH (1:10,000). After being extensively washed in TBS Tween, the membrane was incubated with horseradish peroxidase-conjugated anti-mouse or antirabbit IgG (1:10,000; KangChen Bio-Tech) for 1 h at room temperature. Chemiluminescent signals were generated using a SuperSignal West Pico kit (Pierce) and detected by exposure to X-ray film or using a ChemiDoc XRS System (Bio-Rad Laboratories).
RNA interference knockdown of GPR30.
The plasmid used to silence the GPR30 receptor was constructed using the hU6/MCS/ CMV/GFP/SV40/Neomycin vector (Genechem, Shanghai, China). The small interfering (si)RNA sense oligonucleotide sequences were as follows: GPR30 GGG UGA AGC GCC UCA GUU Auu. As a negative control, a random shRNA sequence was inserted into the hU6/MCS/CMV/GFP/SV40/Neo vector. Transfection was accomplished using Lipofectamine 2000 (Invitrogen) and Opti-mem media (GIBCO, Grand Island, NY) according to the manufacturers' instructions.
Quantitative RT-PCR assays. To measure GPR30 mRNA levels following treatment of cells with RNAi, quantitative real-time PCR analysis was performed using primer pairs with the following sequences: GPR30 forward primer, 5=-CGTGCCTCTACACCATCT-3= and reverse primer, 5=-GCACGGAGATGTGGTAGA-3=. To control for sampling errors, quantitative real-time PCR was conducted on the housekeeping gene cyclophilin D using primer pairs with the following sequences: forward primer, 5=-AAGGGCACTGGACCGACAA-3= and reverse primer, 5=-GCCATGCTCAGCAAACC-3=. This analysis was performed routinely on each sample and used as a control. The reaction solution consisted of 2.0 l of diluted RT-PCR product, 0.2 M of each primer pair, and Power SYBR Green PCR Master Mix (Toyobo, Osaka, Japan). The annealing temperature was set at 58°C for GPR30 and 62°C for cyclophilin D, and the number of amplification cycles was set at 38 cycles. The absolute mRNA levels in each sample were calculated according to a standard curve that was constructed using serial dilutions of known amounts of specific templates and the corresponding cycle threshold (Ct) values. The results are displayed as the normalized ratio of the target gene over cyclophilin D. The specificity of the primers was verified by both agarose gel electrophoresis and sequencing of the PCR products.
Statistical analysis. Statistical analysis was performed using Student's t-test with nonpaired comparisons or paired comparisons when appropriate. Values are expressed as the mean Ϯ SE, with n as the number of cells tested. P Ͻ 0.05 was used to denote the significant difference between groups. When multiple comparisons were made, data were analyzed by a one-way ANOVA test.
Chemicals. REV, G15, phorbol 12-myristate 13-acetate (PMA), forskolin, cytosine1-␤-D-arabinofuranoside, 12-(2-cyanoethyl)-6,7,12,13-
, poly-L-lysine, and DMEM were purchased from Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal antibodies against phosphorylated PKC were purchased from Cell Signaling Technology. Fetal calf serum, heat inactivated horse serum, and antibiotic-antimycotic solutions were obtained from GIBCO Life Technologies. REV solutions were prepared extemporaneously and gravity ejected for 1 to 2 min from MSC-200 Manual Solution Changer (Bio-Logic-Science Instruments). It was first dissolved in DMSO and then diluted in the bath with a final DMSO concentration Ͻ0.1%. The 0.1% of DMSO did not produce the significantly effect on K v2.2 currents.
The drug was ejected by gravity for 40 -60 s from MSC-200 Manual Solution Changer (Bio-Logic-Science Instruments). We tested the exact dilution rate by perfusion of a high concentration potassium solution. The exact dilution rate and the time for the drug to reach maximal concentration around the cell have been evaluated from the resting membrane potential shift recorded in response to perfusion of 50 mM K ϩ solution. By using Goldman-Hodgkin-Katz equation, we figured out that the drug was diluted ϳ3.4 times after it got to the cell surface, and the time for the drug to reach maximal concentration around the cell was 3 s.
RESULTS
It was previously demonstrated that REV could reversibly inhibit I K channels in primary cultured rat hippocampal neurons (13) . Therefore, we first confirmed the effect of REV on I K channels with primary cultured CGNs that possess a rich I K . The I K was evoked by 160-ms depolarizing pulses to ϩ50 mV from holding potentials of Ϫ80 mV (Fig. 1A) . The REV was ejected by gravity for 30 s, and the drug was diluted ϳ3.4 times after it got to the cell surface, and the time for the drug to reach maximal concentration around the cell was 3 s (see METHODS). Application of REV significantly inhibited I K , and the REVinduced the inhibition of I K was 50.5 Ϯ 2.0% (n ϭ 6), 46.0 Ϯ 1.8% (n ϭ 8), and 51.6 Ϯ 2.2% (n ϭ 5) in the presence of 10, 30, and 100 M of REV, respectively (Fig. 1A ). There were no significant differences among these three concentrations of REV. Next, experiments were performed with HEK-293 cells transfected with a pEGFPN1 vector encoding either the K v 2.1 or K v 2.2 ␣-subunit. After a 48-h transfection, cells with green fluorescence were used for recordings. Thus we next investigated the mechanism of REV on Kv2.2 currents. Figure 2A shows that the inhibitory effect of REV on Kv2.2 was reversible and mildly concentration-dependent ( Fig.  2A) . REV at concentrations of 1 M (n ϭ 5) or 5 M (n ϭ 6) did not significantly inhibit K v 2.2 (P Ͼ 0.05 by Student's t-test). In contrast, 10 M, and 100 M REV inhibited K v 2.2 by 28.36 Ϯ 2.69% (n ϭ 12), 29.2 Ϯ 1.73% (n ϭ 5), and 33.47 Ϯ 2.08% (n ϭ 8), respectively (Fig. 2B) . The magnitude of Kv2.2 inhibition was not significantly different between the three concentrations (P Ͼ 0.05, by one-way ANOVA). When the REV concentration was increased to 500 M, the inhibition of K v 2.2 by REV was 56.8 Ϯ 2.93% (n ϭ 5). Because the solubility of REV is low at concentrations Ͼ500 M, higher REV concentrations were not tested. We also examined the effect of DMSO on K v 2.2 because REV was dissolved in 1% DMSO as the carrier solvent. Figure 2C shows typical current recordings and confirms that 1% DMSO did not affect the K v 2.2 current (Fig. 2 , B and C; n ϭ 5).
We then studied the effects of REV on the activation and inactivation of the K v 2.2 current using different experimental protocols. In the voltage activation protocol, the membrane potential was held at Ϫ80 mV and the K v 2.2 current was evoked by a 200-ms depolarizing pulse from a first pulse potential of Ϫ60 to ϩ60 mV in 10-mV steps at 10-s intervals (Fig. 3A) . REV significantly reduced the current amplitude throughout the activation voltage range when the depolarizing pulse was Ͼ0 mV (Fig. 3B) . We obtained the I K activation curve by plotting the normalized conductance as a function of the command potential. Data were then analyzed using the equation
, where G K is the membrane K ϩ conductance, V m is the membrane potential, and V rev is the reversal potential for K ϩ . As shown in Fig. 3C , the activation curve shifted slightly to the left in the presence of REV. The current was half-activated at 15.4 Ϯ 1.3 and 10.14 Ϯ 1.7 mV in the absence and presence of 30 M REV, respectively (n ϭ 14; P Ͻ 0.05, using a paired Student's t-test). These data suggest that REV treatment can partially modify the voltage dependence of Kv2.2 channel steady-state activation.
To study the effects of REV on steady-state inactivation of the Kv2.2 channel, cells were held at Ϫ80 mV and a 1-s conditioning prepulse from Ϫ60 to ϩ60 mV in 10-mV increments was applied. The conditioning prepulse was retuned to Ϫ80 mV for 20 ms before the test pulse to ϩ60 mV (Fig. 4A) . Steady-state inactivation curves of K v 2.2 current were obtained by peak current amplitudes plotted against the prepulse potential (Fig. 4B) . After normalizing each current peak to the maximal current amplitude obtained from the Ϫ80-mV prepulses as a function of the conditioning prepulse potential, we obtained an inactivation curve of I K and calculated the Vh 50 (the voltage at which the current amplitude was half-inactivated). As shown in Fig. 4 C , the inactivation curve shifted to the right by the application of REV. The half-maximal inactivation voltage obtained was 17.1 Ϯ 2.7 and 23.7 Ϯ 2.2 mV in the absence and presence of 30 M REV, respectively (n ϭ 11; P Ͻ 0.05, using a paired Student's t-test), suggesting that REV treatment partially modified the voltage dependence of K v 2.2 channel steady-state inactivation.
Our previous study indicated that K v 2.1 was significantly modified by the cAMP/PKA pathway (19) . Thus we studied the effects of REV on K v 2.2 current in the presence of forskolin, an adenylate cyclase activator, or Rp-cAMP, a specific inhibitor of cAMP-dependent protein kinase (PKA) activation. Perfusion of cells with 20 M forskolin or 10 M Rp-cAMP alone did not affect K v 2.2 current amplitude; furthermore, in the presence of these compounds, REV still significantly inhibited K v 2.2 currents by 31.96 Ϯ 1.68% (n ϭ 5) and 29.56 Ϯ 1.44% (n ϭ 5), respectively (Fig. 5, A and B) . Likewise, when the selective PKA antagonist H-89 was added into the patch pipette solution, 30 M REV inhibited K v 2.2 currents by 29.28 Ϯ 2.0% (n ϭ 5), indicating that the PKA pathway could not abolish the inhibitory effects of REV on K v 2.2 current (Fig. 5, C and D) . Our results suggest that the cAMP/PKA pathway does not contribute to REV-mediated inhibition of K v 2.2 currents.
We next studied the effects of REV on K v 2.2 current in the presence of a PKC activator or inhibitor to address whether the PKC pathway was involved in REV-mediated inhibition of K v 2.2 currents. Perfusion of cells with 50 M PMA, an activator of PKC, in the bath solution provoked a gradual decrease in K v 2.2 current amplitude (28.6 Ϯ 0.82%, n ϭ 5) similar to that produced by REV. Moreover, in the presence of PMA, the REV-induced inhibition of K v 2.2 current was reduced to 1.2 Ϯ 1.3% (Fig. 6A) . REV-induced inhibition of K v 2.2 current was reduced to 3.76 Ϯ 0.86% (n ϭ 5) when 10 M bisindolylmaleimide (Bis), a broad-spectrum PKC inhibitor, was used in the pipette solution (Fig. 6B) . Gö6976, a selective PKC␣ antagonist, was used to explore the role of this PKC isoform in the inhibitory effect of REV on K v 2.2 currents. Figure 6C shows that 30 M REV inhibited K v 2.2 currents by 2.48 Ϯ 1.2% (n ϭ 6) in the presence of 1 M Gö6976 in the pipette solution, indicating that PKC-␣ is involved in the REV-induced inhibitory effects on Kv2.2 currents. Statistical analysis of these results (Fig. 6D) suggests that inhibition of the PKC pathway suppressed the REV-induced K v 2.2 current decrease. In addition, the steady-state activation and inactivation properties of K v 2.2 channels in the presence of PMA were similar to those observed following treatment with REV. After addition of PMA (50 M) to the bath solution, the steady-state activation curve was shifted to the left, from 15.48 Ϯ 1.35 to Cells were held at Ϫ80 mV and then a 1-s conditioning prepulse from Ϫ60 to ϩ60 mV in 10-mV increments was applied. Conditioning prepulse was retuned to Ϫ80 mV for 20 ms before the test pulse at ϩ60 mV. Voltage protocol is shown below the current recordings. B: steady-state inactivation curves of Kv2.2 current in the absence or presence of REV. Abscissa shows the conditioning prepulse potential. C: peak current amplitudes normalized to the maximal currents was plotted against the prepulse potential. Normalized current values were fitted to a Boltzmann function. Steady-state inactivation curve was significantly shifted by REV towards the hyperpolarization potential. Data shown are the means Ϯ SE from 11 cells.
5.0 Ϯ 1.4 mV (n ϭ 14), and the inactivation curve was shifted to the right, from 17.07 Ϯ 2.7 to 23.75 Ϯ 1.12 mV (n ϭ 12; Fig. 6, E and F) .
It was previously reported that REV may act as a ligand of steroid receptors to active intracellular signal transduction. In addition, GPR30 is an oestrogen-receptor involved in the rapid actions elicited by estrogen (26) . Thus we sought to identify whether the GPR30 receptor might mediate the REV-induced inhibition of K v 2.2 currents. Application of G15, GPR30 receptor antagonist, abolished the REV-induced inhibitory effect on the K v 2.2 current (Fig. 7A) . In the presence of 1 M G15, the inhibition of K v 2.2 produced by REV was reduced to 1.4 Ϯ 0.92% (n ϭ 5) and was significantly different from the effect induced by REV alone (Fig. 7D) . GPR30 receptors are G protein-coupled receptors that mediate multiple signal transduction pathways (10) . This pathway was tested by adding GTP␥S (10 M) to the pipette solution. Internal infusion of GTP␥S (10 M) resulted in the gradual suppression of K v 2.2 current amplitude to 29.31 Ϯ 1.02% (n ϭ 6) after membrane rupture (Fig. 7B) . Moreover, following the reduction in K v 2.2 current by internal application of GTP␥S, REV induced average reductions in K v 2.2 current of 1.29 Ϯ 0.84% (n ϭ 6). E 2 , an oestrogen that activates the ER, modulated the K v 2.2 current. The data obtained from five cells indicated that 10 M E 2 mimicked REV and reduced the K v 2.2 current by 33.69 Ϯ 1.87% (Fig. 7, C and D) . We also tested if the HEK-293 cells expressed the GPR30 receptor with PCR techniques. Figure 7E shows that GPR30 mRNA was detected with PCR in HEK-293 cells. These data suggest that the GPR30 receptor is required for REV-induced inhibition of K v 2.2 current.
To further ascertain whether GPR30 mediates the REVinduced inhibition of K v 2.2 currents, shRNA-mediated knockdown of GPR30 expression was performed. Concurrently, the efficiency of the RNAi knockdown of GPR30 was determined in HEK-293 cells, which endogenously express this receptor. Quantitative RT-PCR data showed that transfection of GPR30 shRNA significantly reduced GPR30 mRNA expression in the HEK-293 cells (Fig. 8A) . Moreover, after knockdown of GPR30 expression, the effect of REV on K v 2.2 was attenuated, while the current amplitude in untreated cells was not significantly different at 97.26 Ϯ 3.68% (n ϭ 7) of the control (Fig.  8B) . Statistical analysis showed that the effect of REV following RNAi knockdown of GPR30 was significantly different from that induced by REV alone (Fig. 8C) . This result supports the role of GPR30 in the modulation of Kv2.2 currents by REV.
Lastly, we confirmed that the PKC signaling pathway was activated by REV and the ER by measuring the levels of phosphorylation of PKC (pPKC) with two types of antibodies, one specific for PKC-␣ and PKC-␤ and another selective for PKC-␦ and PKC-. Western blotting showed that phosphorylation of PKC-␣ and PKC-␤ was significantly increased by REV. After treatment of cells with REV for 2, 5, and 10 min, the levels of pPKC-␣ and pPKC-␤ relative to untreated control were increased by 18.18 Ϯ 1.24, 36.63 Ϯ 2.42, and 36.88 Ϯ 2.41%, respectively. Moreover, the effect of PKC-␣ and PKC-␤ activation by REV was inhibited by G15. In the presence of G15 for 5 min, REV-induced pPKC levels were decreased to 0.8 Ϯ 1.06% (n ϭ 3) and significantly different from the effect induced by REV alone when compared with untreated controls (Fig. 9A) . Consistent with the current recording, the level of pPKC-␣ and pPKC-␤ activated by REV could be enhanced by E 2 (Fig. 9B) . In contrast, the levels of phosphorylation of PKC-␦ and PKC-were not affected by REV (Fig. 9C) . After treatment of cells with 30 or 100 M REV, the levels of pPKC-␦ and pPKC-were lightly increased by 3.46 Ϯ 0.03 and 4.87 Ϯ 0.04% (n ϭ 3), without significant different from the untreated controls.
DISCUSSION
Although REV exists as both cis-and trans-isomeric forms, the trans-isomer is the stable form of REV that plays a role in nearly all of its biological actions (9, 11, 13, 17) . Therefore, we studied only the effect of the trans-isomer of REV.
Previous studies associated with ion channel regulation indicated that REV modified ion channels by different mechanisms that were dependent on the cell model used. In human umbilical vein endothelial cells, REV significantly activated large conductance Ca 2ϩ (BK) channels in both whole cell and inside-out configurations (6). However, REV has a concentration-dependent inhibitory effect on I K channels in primary cultured rat hippocampal neurons and L-type Ca 2ϩ channels in A7r5 vascular myocytes (5, 13) . Alternatively, the antiallodynic action of REV was associated the nitric oxide-cyclic GMP-protein kinase G-K ϩ channels (3). Although these data indicated the effect of REV on multiple channels, the molecular mechanisms of this compound are not well clarified. Our data presented here indicate that REV inhibits K v 2.2 ␣-subunits, the main contributor of the I K channel, through the nongenomic actions of the oestrogen receptor and by activating the PKC pathway.
Even though the ␣-subunits of K v 2.2 and K v 2.1 channels share many properties, previous studies suggest the K v 2.1 ␣-subunit is more biologically relevant based on its function, modulation, and phosphorylation sites (19, 27, 33, 48 ) when compared with the K v 2.2 ␣-subunit (46) . Although recognition of K v 2.2 functionality has substantially increased in the last several years, previous studies mainly focused on the subunit contribution to the formation of the action potential (21, 22) . We report for the first time that K v 2.2 can be inhibited by REV through the surface membrane receptor of the oestrogen and that it can be significantly modified by the PKC pathway rather than the PKA pathway. Moreover, it is highly likely that the neuroprotective activities and neuron excitability of REV (39, 43) may be due to oestrogen receptor activation and K v 2.2 current inhibition. Thus our data have important significance for the recognition of the neurobiological role of REV and for the understanding of K v 2.2 channel functioning and modulation.
REV was reported to be a phytoestrogen, and it binds to the oestrogen receptor and activates transcription in different test systems (14) . Recently, an orphan G protein-coupled receptor, GPR30 was identified as a new estrogen-receptor involved in the rapid actions elicited by oestrogen (26) . In our study, REV-induced inhibition of K v 2.2 currents occurred rapidly, suggesting that this was a nongenomic effect that occurred independently of gene transcription. However, this effect might result from the activation of intracellular signaling pathways. The PKC family comprises at least 12 serine/threonine kinase isozymes and is responsible for transducing many cellular signals that regulate the activity of different plasma membrane proteins, including ion channels (18, 30) . The ability of REV to activate or inhibit PKC activity is dependent on cell types. In the present study, we provide evidence that REV blocked K v 2.2 channels by activating PKC, a result similar to the report by Han et al. (17) that describes a significant increase in PKC phosphorylation after treatment of hippocampal neurons with trans-REV. However, our results are in contrast to those of Slater et al. (40) in which REV inhibited membraneassociated PKC-␣ activity in model lipid vesicle membranes using an in vitro assay system. The discrepancy in the action of REV on PKC activity is possibly due to the differences between lipid vesicle membranes and HEK-293 cells; for example, the presence or absence of the interaction with other membrane-associated or cytoplasmic proteins, such as the downstream of ER and GPR30. REV-induced PKC activity was eliminated by ER and GPR30 antagonists in our study, suggesting that ER and GPR30/G protein mediate activation of PKC, rather than a direct action on PKC by REV.
Interestingly, our data indicated that REV-induced inhibition of K v 2.2 currents and activation of PKC required a threshold REV concentration of 10 M. Moreover, the inhibitory effect of REV was not significantly different between the concentrations of 10 and 100 M. This effect is similar to that observed for REV-induced inhibition of I K in rat CGNs. Our results are in contrast to previous reports of the effect of REV on BK channels in human umbilical vein endothelial cells (6) , I K channels in primary cultured rat hippocampal neurons (13) , and L-type Ca 2ϩ channels in A7r5 vascular myocytes (5).
However, Chen et al. (6) showed that REV could activate BK channels in inside-out patches and that blockade of the oestrogen receptor with tamoxifen had no effect on REV-stimulated BK channel activity. The role of GPR30 in REV-induced inhibition of I K in hippocampal neurons and of L-type Ca 2ϩ channels in A7r5 vascular myocytes has not been elucidated. The diverse effects of REV might reflect variations in its mechanism of action. It is possible that REV-induced K v 2.2 inhibition in HEK-293 cells involves activation of GPR30 receptors rather than direct channel blockade. Differences in the effect of REV might also arise due to the differential action of REV on cell surface vs. intracellular transmembrane GPR30 receptors (34) . Another interesting finding is that REV only modulated K v 2.2 and not K v 2.1. Previous reports indicated K v 2.1 possesses a 68 score in the cytoplasmic COOH terminus as a strong consensus phosphorylation site (27, 33) modified by the cAMP/PKA pathway (19, 24) but not PKC. However, activating or inhibiting cAMP/PKA alone did not modify K v 2.2 current; moreover, activating PKC reduced K v 2.2 current implying that the channels might be phosphorylated. A study by Blaine et al. (4) using chimeric transcripts between K v 2.1 and K v 2.2 showed that a carboxy tail domain, proxC, is found in vertebrate K v 2.2 subunits but not any other protein, including K v 2.1. ProxC is produced from K v 2.1 in developmental posttranslational modifications. Interestingly, the primary sequence of proxC predicts consensus sites for PKC, casein kinase 2, and tyrosine phosphorylation (4) . Consistent with this hypothesis, REV can significantly stimulate PKC activity but does not alter PKA activity (data not shown); indeed, this may be the reason why REV significantly inhibited the K v 2.2 current rather than K v 2.1 current. Direct evidence, such as crystal structure analysis or proxC mutation, will be necessary to support this hypothesis. Our present study provides the first evidence that REV inhibits K v 2.2 current, a component of the I K channel in rat CGNs and cortical neurons. We showed also that REV promoted PKC activation through GPR30 receptors. Although some recent studies have revealed the potential neuroprotective and neuroexcitability action of REV, the relevance of our findings to this function needs to be demonstrated in future studies.
